Nuevos sistemas de liberación controlada de tolcapona para el tratamiento de la enfermedad de Parkinson
- CASANOVA SEGOVIA, YAQUELYN
- María Sofía Elisa Negro Álvarez Director
- Emilia María Barcia Hernández Director
Defence university: Universidad Complutense de Madrid
Fecha de defensa: 17 March 2022
- Juan José Torrado Durán Chair
- Karla Slowing Barillas Secretary
- Concepción Martínez Sancho Committee member
- Carolina Hurtado Marcos Committee member
- María Consuelo Montejo Rubio Committee member
Type: Thesis
Abstract
Parkinson's disease (PD) is a complex neurodegenerative disorder with a heterogeneous presentation. To date there is no cure for the disease however, there are several drugs that can act controlling the symptoms along the progression of the disease in order to maintain the quality of life of the patients. Furthermore, given that it is the second most common neurodegenerative disorder after Alzheimer's disease, and that its main risk factor is age, Parkinson's disease is increasingly posing a public health challenge.Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that is administered with levodopa to control motor fluctuations in PD. Selective and reversible inhibition of COMT leads to a reduction in the catabolism of levodopa to 3-O-methyldopa, resulting in increased availability of dopamine in the brain, thereby allowing for a reduction of total daily dose of levodopa...